Clinical trials: Borderline Resectable Carcinoma
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Unfortunately, despite the best clinical efforts and breakthroughs in biotechnology, most patients diagnosed with pancreatic cancer continue to die from the rapid progression of their disease.
- Conditions
- Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
- Trial name
- PILLAR (NCT01836432)
- Testing
- FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation
- Where
- 32 sites in United States
- Volunteers
- 302 people
- Sponsor
- NewLink Genetics Corporation
PDAC - Pancreatic Ductal Adenocarcinoma, FAP
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC.
- Trial name
- FAPI-46 PDAC (NCT05262855)
- Testing
- [68Ga]FAPI-46
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- SOFIE
Non-small Cell Lung Cancer
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
The purpose of this study is to assess efficacy and safety of neoadjuvant durvalumab in combination with platinum-based chemotherapy (CT) given as initial therapy after cancer diagnosis followed by either surgery and adjuvant…
- Trial name
- MDT-BRIDGE (NCT05925530)
- Testing
- Durvalumab
- Where
- 49 sites in United States, Austria and 9 more
- Volunteers
- 142 people
- Sponsor
- AstraZeneca
Pancreatic Carcinoma
CEB-01 in Locally Resectable Pancreatic Cancer
The CEB-01 implant is a membrane containing SN-38, the active metabolite of irinotecan, an already authorized chemotherapeutic agent.
- Trial name
- NCT06538857
- Testing
- Standard surgery, CEB-01
- Where
- 4 sites in Spain
- Volunteers
- 39 people
- Sponsor
- CEBIOTEX
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
Unfortunately, despite the best clinical efforts and breakthroughs in biotechnology, most patients diagnosed with pancreatic cancer continue to die from the rapid progression of their disease.
- Trial name
- NCT02405585
- Testing
- mFOLFIRINOX, Algenpantucel-L Immunotherapy, SBRT
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- NewLink Genetics Corporation